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Abstract. The purpose of this mini review is to discuss the use of physiologically-based drug absorption
modeling to guide the formulation development. Following an introduction to drug absorption modeling,
this article focuses on the preclinical formulation development. Case studies are presented, where the
emphasis is not only the prediction of absolute exposure values, but also their change with altered input
values. Sensitivity analysis of technologically relevant parameters, like the drug’s particle size, dose and
solubility, is presented as the basis to define the clinical formulation strategy. Taking the concept even
one step further, the article shows how the entire design space for drug absorption can be constructed.
This most accurate prediction level is mainly foreseen once clinical data is available and an example is
provided using mefenamic acid as a model drug. Physiologically-based modeling is expected to be more
often used by formulators in the future. It has the potential to become an indispensable tool to guide the
formulation development of challenging drugs, which will help minimize both risks and costs of
formulation development.
KEYWORDS: clinical; design space; drug absorption; formulation; parameter sensitivity; physiologically-
based modelling.
INTRODUCTION
Today’s pharmaceutical Industry is facing a productivity
crisis. Fewer drugs are approved despite constantly increasing
development costs (1). Research-based companies have to
decrease their attrition rates to cope with the situation and to
retain their competitiveness (2). One of the key problems is
to overcome the biopharmaceutical hurdle that is raised by
poorly soluble drug candidates. The issue can be addressed
by an early ADME profiling to better assess the develop-
ability of a drug (3). Such a profiling is nowadays not only
conducted by means of in vitro experiments, but also by
computational methods (4,5). The well known Lipinski rules
(6) can help in anticipating drug absorption hurdles and more
recently, some quantitative structure bioavailability relation-
ships (QSBR) were proposed leading to a more refined
estimate of the drug absorption (7–15). An alternative to the
QSBR approach is the concept of the absorption potential
(16) or the estimation of a maximal absorbable dose (17).
A reliable prediction of a drug’s absorption and/or
bioavailability is not only important for the selection of a
candidate, but is equally critical for its subsequent pharma-
ceutical development. However, in the advanced phase of
development, a more detailed understanding of the drug
absorption process is needed. Issues of incomplete absorp-
tion, non-linear exposure and food effects should be consid-
ered early on as a function of the dose or of other formulation
parameters. This refined drug absorption modeling generally
requires physiologically-based pharmacokinetic models. A
pioneer physiologically-based model was proposed by Yu et
al. (18–20) It was possible to model experimental data
assuming seven physiological compartments in series. Incor-
poration of an absorption step led to the compartmental
absorption and transit model (CAT) (20). The CAT model
was an important step towards physiologically-based drug
absorption modeling. However, it did not include dissolution
of solid particles. The simulations were therefore confined to
those drugs, the dissolution of which is not rate limiting. In a
further modification step to the CAT model, additional
physico-chemical processes were considered. A pH-depen-
dent solubility was introduced, as well as dissolution and
precipitation steps. Drug absorption from the stomach and
colon was added, as well as physiological characteristics of the
absorption surface area and drug transporters. This resulting
new model was called the advanced compartmental absorp-
tion transit model (ACAT) (21) and forms the basis of the
commercial software GastroPlus™ (Simulations Plus, USA).
A large set of differential equations can simulate the above
mentioned absorption processes and a more recent version of
GastroPlus™ further includes a physiologically-based dispo-
sition model. Apart from GastroPlus™, there are additional
473 1550-7416/08/0300-0473/0 # 2008 American Association of Pharmaceutical Scientists
The AAPS Journal, Vol. 10, No. 3, September 2008 (# 2008)
DOI: 10.1208/s12248-008-9054-3
1University of Applied Sciences Northwestern Switzerland, Institute
of Pharma Technology, Gründenstr., 4132, Muttenz, Switzerland.
2To whom correspondence should be addressed. (e-mail: martin.
kuentz@fhnw.ch)integrated dynamic models available as commercial software,
like the program PK-SIM® (Bayer Technology Services,
Germany). It is a software package for whole-body physio-
logically-based pharmacokinetic modeling. The underlying
model is based on a homogenous tube, however, assuming a
continuous intestinal transit function. It is interesting to note
that the beginning of such convection-dispersion models dates
back to the early 1980s (22,23). The modified convection–
dispersion model (24) underlying PK-SIM® was validated in
rats (24), humans (25) and most recently also in monkeys
(26). As an integrated model it is able to capture pH-
dependent solubility, drug dissolution, as well as the modeling
of transporters and intestinal drug clearance.
Besides the ACAT and dispersion-convection models,
other homogenous absorption models exist in the literature
(27–29) and also a heterogeneous tube model was published
(30,31). However, the homogenous models are of more
practical interest due to their commercial availability as
software, like GastroPlus™ or PK-SIM®. The mechanistic
character of the models allows testing of mechanistic assump-
tions. Such hypothesis driven simulations are of special
interest to guide formulation development. In the preclinical
phase, absorption modeling can aid defining a formulation
strategy for first-in-man studies. Once initial pharmacokinetic
information is available, further opportunities are given to
refine model parameters. The modeling and simulation with
refined parameters can further support formulation develop-
ment for the clinical phases 2 and 3, or even for the market.
DEFINITION OF THE CLINICAL FORMULATION
STRATEGY FOR PHASE 1 STUDIES BASED
ON PHYSIOLOGICAL MODELS
OF DRUG ABSORPTION
Bringing a new drug to the market is an endeavor, and
biopharmaceutical issues are often revealed at a rather late
stage of the development phase. Insufficient bioavailability or
non-linearity and variability of drug exposure generally mean
increased resource investment in formulation development.
In some cases, a change of the selected formulation strategy is
necessary and adhering to the original timelines is often no
longer possible. Therefore, formulation changes are costly
and may delay the time to market. It is evident that early
anticipation of such biopharmaceutical issues can streamline
the development process leading to considerable cost savings.
The physiologically-based pharmacokinetic models (PBPK)
are here of special interest, as it is possible to predict
pharmacokinetics in man (32). The model parameters are
related to the compound, as well as to the formulation. Input
parameters like drug solubility, pKa or effective permeability
can itself be calculated resulting in predictions from chemical
structure alone. The comparison of such models without
experiments with the results from simulations, in which
measured data were used (29), showed better prediction
accuracy for the latter case. Accordingly, it seems important
to use measured input data for drug absorption simulations
during the drug development phase. Suitable in vitro experi-
ments can be even tailored in view of the software used. Input
parameters are obtained from physico-chemical profiling of
the compound, from cell culture experiments or even from
animal pharmacokinetics. Due to the incertitude of these
input parameters, any prediction of the human exposure
before clinical Phase 1 must however be treated with caution.
For this reason a procedure according to a scheme as outlined
by Fig. 1 is recommended during the preclinical phase. The
models used should be generally validated with respect to
their physiological default parameters. A subsequent model
of a new drug candidate in a pre-clinical phase should first
attempt to model pharmacokinetics in an animal species.
Once the in vivo results are in good agreement with the
predictions, the step towards a human PBPK model can be
made. The availability of such a human drug absorption
model can help to define the strategy to develop a formula-
tion for phase 1 clinical studies. This definition of a
formulation strategy is particularly challenging with many
poorly soluble drugs. While only limited resources should be
spent at this time of the development due to the high attrition
rate, the phase 1 study should not be jeopardized because of
an insufficient bioavailability. Accordingly, minimal resource
investment has to be balanced against a sound formulation
strategy.
The development of the new drug R1315 is a good
example of how modeling and simulation can guide formula-
tion development (33). R1315 is a hydrogen sulfate, whose
physico-chemical parameters are described in Table I. Due to
its high lipophilicity (logD7.4 of 4.9) and crystallinity (melting
point of 241°C), the drug exhibited a fairly low aqueous
solubility (<1 μg/mL at pH >5). Given the high permeability
and the anticipated dose of about 160–320 mg/day, the drug
was categorized as BCS 2 (34). These preformulation results
denoted the drug as a “biopharmaceutical flag”. However,
it was unclear if the issue was critical enough to justify the
development of sophisticated formulations. Therefore a set
of GastoPlus™ simulations was conducted before an
extensive clinical formulation development was initiated.
Table I summarizes the simulation parameters that were
used. As the estimation of the in vivo solubility is critical,
R1315 was also dissolved in artificial intestinal fluids (35,36)
to obtain experimental values. The highest solubility of
0.2 mg/ml was obtained from simulated gastric fluid
(pH 1.2), whereas in fasted artificial intestinal fluid (pH 6.5)
only 0.05 mg/mL could be dissolved. The obtained solubility
profile was considered as a kind of “worst case”, since the
measurements were conducted at RT. For this reason a set of
simulations was conducted with different solubility–pH pro-
files to scan the range of potential in vivo drug solubilization.
Fig. 1. Flow chart showing how to build a physiologically-based
pharmacokinetic model of drug absorption in the preclinical devel-
opment phase
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means of a parameter sensitivity analysis (PSA). Interestingly,
the simulations showed (Fig. 2) that this parameter was
essentially unchanged in the relevant solubility and particle
size ranges. Another PSA at a higher dose of 320 mg returned
similar simulation data. These results confirmed the BCS
class 2 status for R1315, and that within the relevant solubility
and particle size ranges, no dramatic exposure changes were
to be anticipated.
A mechanistic interpretation can be obtained from the
simulation plot (Fig. 3), in which the dissolved drug is shown
as a function of time. As expected, a considerable fraction of
the dose is first solubilized followed by precipitation in the
intestine. However, the transit time for the given doses
seemed long enough to allow for complete absorption. In
light of these results additional simulations were conducted
by varying the drug’s precipitation time from 180 to 18,000 s,
which again did not greatly affect the predicted exposure.
Thus, the model predicted that drug absorption was rather
insensitive within the relevant dose range and formulation
parameters.
The simulation results provided no rational for a
resource-intensive development of specialized formulations
like solid dispersions or lipid delivery systems. The hypothesis
was made that a standard solid dosage form could be
developed for first studies in man. Prior to this phase 1
formulation development, a simple drug powder blend was
compared with a micellar drug solution in dog studies. The
results showed no significant difference between these
formulations in the relevant dose range (33). This supported
the choice of a standard formulation for phase 1 and
demonstrated how strategic formulations decisions can be
made based on PBPK simulations.
A different case was presented by the drug LAB687
from Novartis (New Jersey, USA) (37). The neutral com-
pound with a MW of 468.5 g/mol and a logP of 4.7 had an
aqueous solubility of about 0.17 μg/mL. This value was
Fig. 2. Parameter sensitivity analysis of the oral bioavailability
following a dose of 160 mg R1315
Table I. Input Parameters for the Drug Absorption Simulation of R1315
Compound Parameters Physiological Parameters PK Parameters
MW: 409.41 g/mol Human fasted condition Body weight: 70 kg
clogP: 5.5 LogD absorption model First pass extraction: 12.5%
pKa: 5.9 Dose volume: 250 mL Blood to plasma concentration ratio: 1
IR capsule: 160 mg Stomach transit time: 0.1 h Clearance estimate: 0.15 L/(h kg)
Lower reference solubility (pH 6.5): 0.002 mg/mL Small intestinal transit time: 3.3 h Volume of distribution: 1.9 L/kg
Precipitation time: 1,800 s Small intestinal radius: 1.2 cm –
Particle density: 1.2 g/mL Small intestinal length: 300 cm –
Effective permeability: 4.4×10
−4 cm s
−1 Colon transit time18 h –
Mean particle size: 5 μm Colon volume: 1,200 mL –
Fig. 3. Modelling of the different drug states upon intestinal
absorption as a function of time for 160 mg (upper figure) and
320 mg R1315 (lower figure)
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mL was obtained from tests in a bile salt solution. Similar to
the previous example, GastoPlus™ simulations were run for
different parameter settings in a dose range of 5–500 mg.
However, the PSA showed some ranges of high exposure
sensitivity for LAB687 based on the solubility of the drug, as
well as a dependence on the particle size. As the inspected
ranges were of technological relevance the simulations raised
concerns for the upcoming formulation development. The in
silico results were also in this case complemented by tailor-
made pharmacokinetic studies in the dog. A standard powder
blend of the drug (micronized) in capsules was compared with
two other formulations. The rationale for the latter formula-
tions was to increase the in vivo solubilization of the drug.
Accordingly, a co-solvent/surfactant solution of Cremophor
was tested together with a solid dispersion of the drug in a
mixture of 3:1 PEG3350 to polysorbate 80. Table II exhibits
the results of this dog PK study. Both biopharmaceutically
enhanced formulations exhibited about 10x higher oral
bioavailability compared to the dry powder blend. Accord-
ingly, the in vivo study in the dog model agreed with the in
silico prediction with respect to the biopharmaceutical hurdle
of LAB687. A strong rationale was given to invest adequate
resources in the formulation development.
The two case studies of the new drugs R1315 and
LAB687 both demonstrate how modeling and simulation of
drug absorption can provide a rational basis for the formu-
lation development strategy. The physiologically-based mod-
els used in both cases measured compound properties to
estimate the pharmacokinetic behavior in humans based on
existing animal data. These adapted physiologically-based
models have a higher quality of input parameters as
compared to generic physiologically-based models that are
used in the clinical candidate selection phase. During the
course of the development, the level of information on the
new drug increases and this can be reflected by a higher
model predictability. However, before the drug is tested in
humans there is always a given level of incertitude. Parrott et
al. (2006) (32) reviewed the predicted versus the observed
AUC of 19 Roche compounds. Interestingly, 76% of the
predictions using the physiologically-based modeling ap-
proach was within a two-fold range of the observed results.
This accuracy seems good enough to anticipate the human
exposure and to guide decision-making during the develop-
ment of a phase 1 formulation.
MODELING OF FACTOR INTERACTIONS
TO SUPPORT FORMULATION DEVELOPMENT
A major step in the development of a drug as well as in
the evolution of an absorption model is the first testing in
man. The availability of human exposure data opens new
doors for the modeling capabilities, leading for example to
the model’s next level of complexity. Tubic et al.( 38)
proposed an Advanced Compartmental and Transit model
for the absorption of the drug Talinolol. P-glycoprotein (P-
gp)-mediated efflux for this drug was assumed, which needed
an estimation of the transport parameters Km and Vmax. The
adapted physiologically-based model captured well the non-
linearity of the exposure with increasing doses between 25
and 400 mg. The authors also performed a set of simulations
in a virtual clinical trial. Accordingly, the drug absorption
simulation estimated not only the exposure for a given dose,
but provided further a variability forecast. This information is
especially valuable for the later stages of the formulation
development. The target specifications of the formulation
could be set on a more rational basis, which could help, for
example, in attempts to increase the bioavailability of a
formulation. The simulations could compare a targeted
formulation effect with the anticipated inter-subject variabil-
ity resulting in a clear view on what can be achieved by means
of the formulation.
A reality-check of a human absorption model occurs when
thedrugproductentersitsfirstclinicaltrials.Havinghumandata
of a drug candidate can not only be used to assess the
predictability of the model, but may also feed-back to the
process of how to find a model in the preclinical phase. Thus, in
vitro tests can be improved with respect to estimating
simulation parameters. Recently physiologically-based model-
ing was used to establish an in vitro/in vivo correlation (IVIVC)
for the BCS class 2 drug glyburide (39). Such computer models
could potentially be used as surrogate for bioequivalence
studies. The risks of a study failure could be better anticipated
in advance, which is of great importance for the later clinical
phases or for generic formulation development.
Once clinical data is available, it is possible to revisit the
in vitro results used for the absorption modeling. Experimen-
tal testing conditions may be improved in the light of human
exposure data. Thus, a recent article (40) questioned the most
widely used composition of simulated gastric fluid (41). The
critique originated from physico-chemical concerns and was
supported by an absorption modeling using GastroPlus™.A
new composition of simulated gastric fluid was proposed (40)
and accordingly, the modeling can be used to further improve
the recipe of simulated intestinal fluids.
The presented examples demonstrate that physiological-
ly-based modeling offers a variety of tools for the formulator
in the later stages of the formulation development. It seems
that the full potential of these approaches has not yet been
exploited by the industry. Thus, the last case study of this
article presents another application of drug absorption
modeling at later stages of the formulation development.
Previous examples showed that a single simulation is of less
interest compared to a set of simulations using PSA. It is the
varying exposure depending on changes of technical param-
eters that is critical for the formulation development. The
Table II. Mean Pharmacokinetic Parameters and Their Relative Bioavailability in the Dog Studies for the Three Formulation Approaches
50 mg LAB687 of formulation Tmax (h) Cmax (μg/mL) AUC0–48h(μg h/mL) Frel (%)
Surfactant solution 1–2 1.16 6.96 100
Solid dispersion 1–2 0.803 6.90 99.1
Dry blend 1 0.128 0.681 9.8
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simulations by varying one parameter at a time. The routine
can be repeated with other parameters and the results are
typically presented in a plot like Fig. 2. As good as the
procedure is to study factor influences, it is not adequate to
reveal factor interactions. Such an interaction exists when a
given factor depends on the level of another. To study factor
interactions, the computer experiments are conducted accord-
ing to a special design. Such statistical designs are often used
in experimental pharmaceutics to study factors, interactions,
and response surfaces (42,43). The conduct of computer
experiments according to a statistical design goes beyond the
single factor PSA so that an entire drug absorption design
space (DADS) can be evaluated. The response surface may
be mapped according to statistical model equations and in the
future the physiologically-based software may calculate each
point of the response surface by an automated routine. The
following example shows the principle of DADS using
mefenamic acid as a model substance.
The program PK-SIM® employing a modified convec-
tion–dispersion model (24–26) was used for these simulations.
As compound properties for mefenamic acid, we set a MW of
241.3 g/mol, a logP of 3.52, a pKa (apparent) of 6.4 and a
solubility of 46 μg/mL (pH 5.5). The program calculated an
intestinal effective permeability of 2.68×10
−5 cm/s, using as
default physiological parameters of the program (version 3.0)
the fasted human state. A fraction unbound of 1% in
combination with a clearance value of 0.26 l/(h kg) (44) was
set for all simulations of mefenamic acid.
The initial absorption simulation was performed at an
oral dose of 500 mg with an average drug particle size of
100 μm. This average particle size of a monodisperse
distribution was a first approximation of the real particle size
distribution, which was essentially polydisperse (45). Thus, a
simple model of the unmilled drug was obtained and the
predicted plasma profiles were compared with the published
data from a clinical study (45). The plasma profiles turned out
to be in good agreement with the theoretical predictions.
Based on this successful model verification we wanted to
study the effects of dose and particle size, as well as their
interaction in relation to the oral drug exposure.
A four level statistical design (4
2) was conducted with
rather broad factor ranges. The doses were set at 10, 340, 670,
and 1,000 mg and the particle size ranged from 1, 67.33,
133.67 to 200 μm. The simulation results were analysed with
respect to the fraction absorbed, Fa and Cmax using a
statistical software package (Statgraphics Centurion XV).
The factors dose and particle size were found to be highly
significant for Fa as well as for Cmax (p<0.0001). Interestingly,
the interaction of the two factors was also highly significant
(p<0.0001) for both responses. Fig. 4 highlights this finding
by means of an interaction plot. The lower particle sizes result
in practically complete absorption for the extreme doses of 10
as well as 1,000 mg. However, at a particle size of 200 μm, the
Fig. 4. Interaction plot of dose and particle size of mefenamic acid
with respect to the fraction absorbed and maximal plasma concen-
tration, respectively
Fig. 5. Response surface plot of the modelled dose fraction absorbed
and maximal plasma concentration using mefenamic acid as model
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difference between the two doses. Accordingly, the dose
effect on drug absorption only comes into existence when
coarser particles lead to limited dissolution of the drug. Fig. 4
displays also the interaction with respect to the maximal
plasma concentration. The lower dose, being less critical for
complete dissolution of the drug, showed no particle size
effect. However, a pronounced particle size effect was
observed when the dose increased to the higher level of
1,000 mg. The higher dose level was critical from an exposure
perspective, which was also reflected by the response surface
in Fig. 5 (R
2=0.998 for Fa and R
2=0.996 for Cmax). A plateau
of complete absorption was observed within a small particle
size range. However, at a higher particle size, a steep drop of
the absorbed dose fraction was predicted.
The modeling results provide a rational answer to a
typical question in drug development. Should the drug be
milled, or should the unmilled drug be used to save costs?
The model demonstrated that an answer from a biopharma-
ceutical perspective must be given in relation to the dose. For
higher doses of mefenamic acid the model indicated that
milling is required. It seems reasonable to stay clearly in the
plateau range of complete absorption, since in a steeper part
of the response surface erratic absorption as well as high
inter-subject variability must be expected. The plateau
denotes therefore a formulation robustness with respect to
dosage and average particle size. This robust range can also
be observed by inspecting the maximal plasma concentra-
tions, Cmax. Strict linearity for the dose was only predicted
within this range of complete drug absorption (Fig. 5).
In line with our findings based on this model drug, the
authors Hummel and Buchmann (45) found that for a generic
formulation, the milling of mefenamic acid significantly raised
drug absorption and bioavailability, respectively. Batches of
unmilled drug were shown to exhibit a rather course particle
size distribution. The slower dissolution from the coarser drug
was associated with erratic drug absorption and incomplete
bioavailability.
It was argued at the beginning of this decade that a
bioavailability study was indispensable for generic formula-
tions of mefenamic acid. Relying on dissolution data alone
was considered as not being sufficient for this model drug.
However, today the physiologically-based drug absorption
modeling can integrate the critical drug factors for example
the dose or particle size to construct a DADS. Critical ranges
of the drug and of formulation factors may be distinguished
from other parameter ranges, where complete absorption is
anticipated. In the latter part of the DADS, there is no
relevant bioavailability variance expected when comparing
different formulations. Thus, a well founded DADS may in
the future lead to reduced or even omitted clinical bioavail-
ability testing.
CONCLUSIONS
Physiologically-based models go far beyond the sole
purpose of prediction of drug absorption. Their mechanistic
character is of particular advantage once more information is
available on a development compound. The quality of input
parameters can at that point be improved and mechanistic
hypotheses be checked by specially designed experiments.
This procedure can guide the preclinical formulation devel-
opment. The biopharmaceutical hurdles of the drug can be
anticipated early on and a rational may be given for a more
complex formulation development. In this context the pa-
rameter sensitivity analysis is particularly useful. It can
predict exposure based on changes in the compound or
formulation parameters. This concept has the potential to be
further extended to a systematic screening of a drug
absorption design space. Factor interactions become apparent
as well as ranges, wherein a formulation appears to be robust
from a biopharmaceutical perspective. Accordingly, physio-
logically-based modeling offers a variety of tools for a
pharmacist and an excellent opportunity is given for a more
focused and thus cost-effective formulation development.
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